ALNY: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/b605b556-1178-4271-93ed-db11ec8e3586/","filing_uuid":"b605b556-1178-4271-93ed-db11ec8e3586","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/b605b556-1178-4271-93ed-db11ec8e3586/print/","filing_document_content_type":"text/html","income":"30000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Allegra M. Han","dt_posted":"2026-07-16T15:06:23-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 13th Street NW, 2nd Floor","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":313715,"url":"https://lda.gov/api/v1/registrants/313715/","house_registrant_id":39384,"name":"CAPITOL COUNSEL LLC","description":"Government affairs.","address_1":"700 13th Street NW, 2nd Floor","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"TRACEY A. GRAY","contact_telephone":"+1 202-861-3200","dt_updated":"2026-07-31T14:55:49.985763-04:00"},"client":{"id":64701,"url":"https://lda.gov/api/v1/clients/64701/","client_id":64701,"name":"ALNYLAM PHARMACEUTICALS, INC.","general_description":"Pharmaceutical manufacturer.","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-02-01"},"lobbying_activities":[{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143156,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":110089,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"CARROLL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}